Q-omics provides the consensus-scored RN7SL535P profile across patient tissues and cancer cell-line models. RN7SL535P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RN7SL535P is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, RN7SL535P RNA expression shows 16,533 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BLCA, and THYM as cancer lineages where RN7SL535P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL535P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL535P survival associations across molecular data types. RN7SL535P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL535P RNA expression–survival associations across cancer types. High RN7SL535P expression shows unfavorable associations in THCA, KICH and LGG, but favorable associations in HNSC, UCEC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify HNSC as the clearest survival context for RN7SL535P RNA expression.
This table summarizes RN7SL535P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL535P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL535P shows higher tumor expression in BLCA, COAD, HNSC, UCEC, KIRC and KIRP. The BLCA box plot shows higher RN7SL535P RNA expression in tumor versus normal tissue (log2 FC = +0.770, t-test p < 0.001).
This table shows molecular features associated with RN7SL535P in patient tissues and cancer cell lines. In patient samples, RN7SL535P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
